June 9 (Reuters) - Immuron Ltd (IMC) :
- US DOD NAVAL MEDICAL RESEARCH CENTER REQUESTS MEETING WITH FDA FOR GUIDANCE ON TWO PHASE 2 TRIALS TO PREVENT ACUTE INFECTIOUS DIARRHEA
- IMMURON LTD - TWO HUMAN PHASE II CLINICAL TRIALS TO BE CONDUCTED IN 2021
- IMMURON - ONE TRIAL TO FOCUS ON ABILITY OF HYPERIMMUNE PRODUCT TO PROTECT VOLUNTEERS AGAINST MODERATE TO SEVERE CAMPYLOBACTERIOSIS
- IMMURON - SECOND TRIAL WILL FOCUS ON ETEC INFECTIONS
- IMMURON LTD - NMRC PLANS TO FILE IND APPLICATION LATER THIS YEAR, COMMENCE PHASE 2 CLINICAL STUDIES DURING H1 2021
June 9 (Reuters) - Immuron Ltd (IMC) : US DOD NAVAL MEDICAL...
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
